The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2022 | High-grade vs low-grade chemotherapy in patients with relapsed AML or MDS
Markéta Marková, MD, PhD, Institute of Haematology and Blood Transfusion, Prague, Czech Republic, comments on the results of a study evaluating high-grade versus low-grade chemotherapy in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) as a strategy to manage relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT). Overall, results suggested that high-grade chemotherapy may lead to better remission, but Dr Marková notes that not all patients can be treated with this regimen after they relapse. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
